Alzheimer's disease (AD) so far did not have promising treatment. The accurate and early diagnosis is still the important issue. For these purpose, biomarkers related to diagnosis, clinical course, and other aims have been proposed and reported. Meanwhile, along with the ongoing researches for AD, biomarkers with their own aims are also on the way.
LeeY.The recent decline in prevalence of dementia in developed countries: Implications for prevention in the Republic of Korea. J Korean Med Sci2014, 29(7): 913–918.
2.
LublinA.L., GandyS.Amyloid-beta oligomers: Possible roles as key neurotoxins in Alzheimer's disease. Mt Sinai J Med2010, 77(1): 43–49.
3.
MaggioJ.E., StimsonE.R., GhilardiJ.R., AllenC.J., DahlC.E., WhitcombD.C., VignaS.R., VintersH.V., LabenskiM.E., MantyhP.W.Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci USA1992, 89(12): 5462–5466.
4.
LeeH.J., ZhangY., ZhuC., DuffK., PardridgeW.M.Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J Cereb Blood Flow Metab2002, 22(2): 223–231.
5.
VillemagneV.L., OngK., MulliganR.S., HollG., PejoskaS., JonesG., O'KeefeG., AckermanU., Tochon-DanguyH., ChanJ.G., ReiningerC.B., FelsL., PutzB., RohdeB., MastersC.L., RoweC.C.Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med2011, 52(8): 1210–1217.
